TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33773580

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (40 mg.kg−1 bolus and 20 mg.kg−1.h−1 infusion)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lidocaine (3 mg.kg−1 bolus and 3 mg.kg−1.h−1 infusion)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Magnesium plus lidocaine (equal doses of both drugs)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (isotonic solution)
Number of subjects: 64
Study: 32238166

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT) for 30 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous exercise (CONT) for 30 minutes
Number of subjects: 0
Study: 35005038

Group type: EXPERIMENTAL
Intervention: Text messages (56 messages between 13 and 40 gestational weeks)
Number of subjects: 66
Study: 33291242

Group type: EXPERIMENTAL
Intervention: Survey on age-friendly domains
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on neighborhood parks and streets
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on transportation
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on sidewalks
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on social and educational activities
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on community participation
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on loneliness
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on community connection
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Survey on Internet access
Number of subjects: 656
Study: 32564649

Group type: EXPERIMENTAL
Intervention: SHARe program (weekly eight-session, 12-hour group program)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 62
Study: 33169490

Group type: EXPERIMENTAL
Intervention: Unguided Internet-based cognitive-behavioral therapy (iCBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 128
Study: 36460266

Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT-ARFID)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Psychoeducational Motivation Therapy (PMT)
Number of subjects: 100
Study: 32533883

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (Cu-IUD)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Subdermal implantable contraceptives
Number of subjects: 250
Study: 34758252

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily)
Number of subjects: 5661

Group type: COMPARATOR
Intervention: Ramipril (5 mg twice daily)
Number of subjects: 5661

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 5661

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 5661
Study: 33057643

Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patients (VSP) training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Academic study (Control)
Number of subjects: 120
Study: 35065334

Group type: EXPERIMENTAL
Intervention: Acute stress condition
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-stress control condition
Number of subjects: 80
Study: 32746941

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 358

Group type: COMPARATOR
Intervention: SSRIs (considered as a single group)
Number of subjects: 358
Study: 32259228

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Olaratumab (75 mg/m2 + 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Doxorubicin plus Placebo (75 mg/m2 + placebo)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Olaratumab
Number of subjects: 509

Group type: COMPARATOR
Intervention: Doxorubicin plus Placebo
Number of subjects: 509
Study: 35688272

Group type: EXPERIMENTAL
Intervention: Particulate bone graft filling material (75% autogenous bone chips and 25% deproteinized bovine bone mineral)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unfilled gap (spontaneous bone healing)
Number of subjects: 22
Study: 34480008

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB; 0.3 g/kg body mass) with high-intensity (HI) warm-up
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB; 0.3 g/kg body mass) with low-intensity (LI) warm-up
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with high-intensity (HI) warm-up
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with low-intensity (LI) warm-up
Number of subjects: 12
Study: 36148560

Group type: EXPERIMENTAL
Intervention: Blinded sample size re-estimation (BSSR) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothetical treatment to reduce exacerbation rate
Number of subjects: 0
Study: 32144167

Group type: EXPERIMENTAL
Intervention: Smart bolus calculator informed by real-time insulin sensitivity estimates
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard bolus calculator
Number of subjects: 15
Study: 35098608

Group type: EXPERIMENTAL
Intervention: Self-induced myofascial release protocol using a foam roller
Number of subjects: 25
Study: 32029010

Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone interpersonal psychotherapy (IPT)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard locally available care
Number of subjects: 241
Study: 35918696

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Injection of local anesthetic (IA)
Number of subjects: 38
Study: 33675600

Group type: EXPERIMENTAL
Intervention: Incremental VOR adaptation exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: x1 gaze-stabilizing exercises (control)
Number of subjects: 24
Study: 33084524

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study: 32109991

Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) of amlodipine/losartan/rosuvastatin 5/100/20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Loose Combination (LC) of amlodipine/losartan and rosuvastatin
Number of subjects: 60
Study: 35597226

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 100% of resting motor threshold)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 44
Study: 33025056

Group type: EXPERIMENTAL
Intervention: Unloading brace
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-brace group
Number of subjects: 21
Study: 32486256

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil capsules (2 g per day, 860 mg DHA + 120 mg EPA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 58
Study: 36940782

Group type: EXPERIMENTAL
Intervention: 3D-printed model
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 3D printed picture
Number of subjects: 184
Study: 33657420

Group type: EXPERIMENTAL
Intervention: Tube eyes
Number of subjects: 419

Group type: COMPARATOR
Intervention: Trabeculectomy eyes
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: TVT IRIS Registry tube eyes
Number of subjects: 419

Group type: COMPARATOR
Intervention: TVT RCT tube eyes
Number of subjects: 419
Study: 32658503

Group type: EXPERIMENTAL
Intervention: Active Neurofeedback Training (NFT), 24 sessions, twice a week
Number of subjects: 37

Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 37
Study: 36384746

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (telmisartan 40 mg/day)
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study: 34664527

Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg/day for 12 weeks
Number of subjects: 55
Study: 34950221

Group type: EXPERIMENTAL
Intervention: Xiaoyutang combined with intraperitoneal heat perfusion chemotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intraperitoneal thermal perfusion chemotherapy (Control)
Number of subjects: 96
Study: 32968008

Group type: EXPERIMENTAL
Intervention: Nutritional status including anthropometric measurements, dietary intakes from complementary foods, feeding practices, and micronutrient concentrations.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consumption of fats and oils the previous day.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive nutritional status (growth, nutritional blood biomarkers, dietary intakes, and feeding practices).
Number of subjects: 0
Study: 36322843

Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 10 mg psilocybin
Number of subjects: 233

Group type: COMPARATOR
Intervention: 1 mg psilocybin (control)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Adverse events (all groups)
Number of subjects: 233
Study: 34701532

Group type: EXPERIMENTAL
Intervention: GC4711 (100 mg IV prior to each of 5 consecutive daily SBRT fractions of 10-12Gy)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (in the Phase 2 cohort concurrent with SBRT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: SBRT (5 fractions of 10-12Gy)
Number of subjects: 71
Study: 35766657

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Daclatasvir
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Atazanavir, Daclatasvir, or Sofosbuvir (in combination)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 32833476

Group type: EXPERIMENTAL
Intervention: Stress reactivity assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impact of stress reactivity on temporal discounting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence to cancer control behaviors and treatment compliance
Number of subjects: 0
Study: 33432635

Group type: EXPERIMENTAL
Intervention: Medication Overuse Treatment Strategy trial
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Higher headache frequency
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Migraine preventive medication
Number of subjects: 610
Study: 32291802

Group type: EXPERIMENTAL
Intervention: Full-amplification hearing aids (active)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-amplification hearing aids (sham)
Number of subjects: 13
Study: 35951066

Group type: EXPERIMENTAL
Intervention: Reiki therapy (21 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 32348605

Group type: EXPERIMENTAL
Intervention: Intra-articular methylprednisolone acetate (MPA) 100 mg/joint
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intramuscular methylprednisolone acetate (MPA) 200 mg
Number of subjects: 12
Study: 36278451

Group type: EXPERIMENTAL
Intervention: Recovery-focused therapy plus treatment as usual
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 39
Study: 32014845

Group type: EXPERIMENTAL
Intervention: Intervention group (mHealth team challenge)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 35285308

Group type: EXPERIMENTAL
Intervention: OCT Angiography (OCT-A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: OCT B-scan (OCT-B)
Number of subjects: 64
Study: 33951306

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 20
Study: 32101269

Group type: EXPERIMENTAL
Intervention: ICG group (laparoscopic gastrectomy using near‐infrared imaging after endoscopic peritumoral injection of ICG 1 day before surgery)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Non‐ICG group (conventional laparoscopic gastrectomy)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: ICG group
Number of subjects: 258

Group type: COMPARATOR
Intervention: Non‐ICG group
Number of subjects: 258
Study: 33794675

Group type: EXPERIMENTAL
Intervention: Physical activity‐informed bolus method
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 15
Study: 34919132

Group type: EXPERIMENTAL
Intervention: Electrographic seizure group (ESG) - treated for both electrographic and clinical seizures
Number of subjects: 212

Group type: COMPARATOR
Intervention: Clinical seizure group (CSG) - treated only for clinically detected seizures
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Electrographic seizure group (ESG)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Clinical seizure group (CSG)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (time to suck feeds, seizure burden, brain injury score)
Number of subjects: 212
Study: 35879573

Group type: EXPERIMENTAL
Intervention: bc‐EIS
Number of subjects: 95

Group type: COMPARATOR
Intervention: EVL
Number of subjects: 95
Study: 32869428

Group type: EXPERIMENTAL
Intervention: Concentrated Hybrid Coating (TEOS/GPTMS/Y‐APS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diluted Hybrid Coating (1:3 ratio with distilled water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Saliva)
Number of subjects: 30
Study: 36322060

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SA)
Number of subjects: 248
Study: 32597289

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 17

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 17
Study: 32080123

Group type: EXPERIMENTAL
Intervention: Jujadokseo-hwan (JDH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36180059

Group type: EXPERIMENTAL
Intervention: Nurse-driven rapid response team protocol for suspected sepsis
Number of subjects: 32
Study: 34143234

Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia (IAA) with sevoflurane treatment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Intravenous anesthesia (IVA) with propofol treatment
Number of subjects: 180
Study: 32841251

Group type: EXPERIMENTAL
Intervention: Maternal nontransmitted haplotype score for height
Number of subjects: 10734

Group type: EXPERIMENTAL
Intervention: Maternal transmitted height haplotype scores
Number of subjects: 10734

Group type: EXPERIMENTAL
Intervention: Maternal transmitted BMI scores
Number of subjects: 10734

Group type: EXPERIMENTAL
Intervention: Maternal and paternal transmitted BP scores
Number of subjects: 10734

Group type: EXPERIMENTAL
Intervention: Nontransmitted haplotype score for FPG
Number of subjects: 10734

Group type: EXPERIMENTAL
Intervention: Haplotype scores for T2D
Number of subjects: 10734

Group type: EXPERIMENTAL
Intervention: Paternal transmitted birth weight score
Number of subjects: 10734
Study: 35974352

Group type: EXPERIMENTAL
Intervention: SCT-based training program consisting of six 60-80 min sessions followed by 2-3 follow-up home visits (once a month for each participant)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study: 33844642

Group type: EXPERIMENTAL
Intervention: rhLf
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 33284679

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg/d for 3 days followed by 200 mg/d for 11 days)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Ascorbic acid (500 mg/d followed by 250 mg/d) as a placebo‐equivalent control
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 829
Study: 32498269

Group type: EXPERIMENTAL
Intervention: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (crystal cellulose capsules) for 8 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks (subgroup analysis of 101 subjects without URI)
Number of subjects: 120
Study: 37573352

Group type: EXPERIMENTAL
Intervention: In-centre nocturnal haemodialysis (INHD), 6 to 8 hours thrice-weekly for 6 months
Number of subjects: 68000

Group type: COMPARATOR
Intervention: Conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 hours per session)
Number of subjects: 68000
Study: 34852414

Group type: EXPERIMENTAL
Intervention: Inadequate use of protocol and adherence (identified as a cause of AEs)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Statistical analysis (descriptive and inferential statistics including confirmatory factor analysis)
Number of subjects: 650
Study: 32195863

Group type: EXPERIMENTAL
Intervention: Upper lateral cartilage classified from class I to class V
Number of subjects: 71
Study: 35394961

Group type: EXPERIMENTAL
Intervention: 1-level PLATE
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 2-level CAGE
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 2-level PLATE
Number of subjects: 46

Group type: COMPARATOR
Intervention: 1-level CAGE
Number of subjects: 46
Study: 32179874

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Deprivation index
Number of subjects: 23
Study: 32054510

Group type: EXPERIMENTAL
Intervention: Educational booklet with foot-related exercises (3 times/week for 8 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Recommended foot care by international consensus (no foot exercises)
Number of subjects: 48
Study: 34407342

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab (200 mg intravenously once every 3 weeks for up to 17 cycles)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 994
Study: 32299400

Group type: EXPERIMENTAL
Intervention: Structured Reports (SR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Free-Text Reports (FTR)
Number of subjects: 104
Study: 35118684

Group type: COMPARATOR
Intervention: Placebo-controlled trials in pediatric population
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo-controlled trials in adult population
Number of subjects: 71
Study: 33538409

Group type: EXPERIMENTAL
Intervention: Planning condition (formed one FV plan)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 206
Study: 32427795

Group type: EXPERIMENTAL
Intervention: Health Empowerment Intervention (HEI) consisting of 6 weekly sessions based on the Health Empowerment Theory
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 20
Study: 35881414

Group type: EXPERIMENTAL
Intervention: Task-oriented training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Therapy
Number of subjects: 18
Study: 33862045

Group type: EXPERIMENTAL
Intervention: HIC (Hepatic Insulin Clearance)
Number of subjects: 3311

Group type: EXPERIMENTAL
Intervention: Liver fat
Number of subjects: 3311

Group type: EXPERIMENTAL
Intervention: BMI-related SNPs
Number of subjects: 3311

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 3311

Group type: EXPERIMENTAL
Intervention: HDL
Number of subjects: 3311
Study: 33156995

Group type: COMPARATOR
Intervention: Reference product (metronidazole cream)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.56% MTZ cream (negative control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.95% MTZ cream (negative control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.75% MTZ cream
Number of subjects: 10
Study: 34171823

Group type: EXPERIMENTAL
Intervention: AFGE-AD (integrated, minimal-guidance, adherence-focused self-help intervention)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: AFGE-AO (self-help intervention designed to reduce alcohol use only)
Number of subjects: 689

Group type: COMPARATOR
Intervention: IAU (internet access as usual)
Number of subjects: 689
Study: 32311911

Group type: EXPERIMENTAL
Intervention: 400 μg of the β2‐agonist salbutamol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diesel exhaust (DE)
Number of subjects: 18
Study: 36420278

Group type: EXPERIMENTAL
Intervention: 10-degree reverse Trendelenburg position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Recumbent position (Group 1)
Number of subjects: 60
Study: 32648391

Group type: EXPERIMENTAL
Intervention: Herb-separated moxibustion at Jinsuo (GV 8)-eight-diagram points, applied for 40 min once daily for 8 weeks.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Pinaverium bromide tablets, 50 mg three times a day for 8 weeks.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Tongxieyaofang decoction, one dose a day for 8 weeks, taken separately in two times.
Number of subjects: 126
Study: 35781437

Group type: EXPERIMENTAL
Intervention: Probiotic mouthwash
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 20
Study: 32051193

Group type: EXPERIMENTAL
Intervention: Circulating linoleic acid
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: Circulating α-linolenic acid
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: Circulating arachidonic acid
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: Circulating eicosapentaenoic acid
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: Circulating docosapentaenoic acid
Number of subjects: 24000
Study: 35032651

Group type: EXPERIMENTAL
Intervention: Increased SpO2 targets in hospitals (14 hospitals)
Number of subjects: 8142

Group type: COMPARATOR
Intervention: No change in SpO2 targets in hospitals (7 hospitals)
Number of subjects: 8142
Study: 33813982

Group type: EXPERIMENTAL
Intervention: Computer-based Multi-Sensory Program (MSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32889135

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study: 37468607

Group type: EXPERIMENTAL
Intervention: Motor Training
Number of subjects: 0
Study: 34886078

Group type: EXPERIMENTAL
Intervention: Self-myofascial release (SMR) applied to the posterior part of the sural fascia for 10 min
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Self-myofascial release (SMR) applied to the posterior part of the crural fascia for 10 min
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Self-myofascial release (SMR) applied to any of the SBL segments for 10 min
Number of subjects: 94